Emboline

Emboline, Inc. is a privately held medical technology company based in Santa Cruz, California, dedicated to developing innovative solutions to mitigate embolic complications during transcatheter cardiovascular procedures. The company's flagship product, the Emboliner® Total-Body Embolic Protection System, is designed to capture and remove embolic debris released into the bloodstream during interventions such as transcatheter aortic valve replacement (TAVR). This debris, which can include calcified valve tissue, thrombus, and foreign material, is a significant cause of stroke, cognitive decline, acute kidney injury, and other ischemic complications. The Emboliner system aims to provide comprehensive brain and body protection through its dual-layer Nitinol mesh filter and integrated access port, balancing high blood flow with superior debris capture.

The company was founded in 2011 by Amir Belson, M.D., a prolific physician, innovator, and serial entrepreneur with a history of establishing multiple successful medical device companies. Emboline was built upon a seasoned team with extensive experience in launching medical devices. The company's mission is to enhance patient lives by eliminating TAVR-related stroke and equipping interventional cardiologists with confidence in every procedure.

As a medical technology company, Emboline does not have an investment focus or a portfolio of companies in the traditional sense of an investment firm. Instead, it is a recipient of investment, having recently secured $20 million in growth capital from Trinity Capital Inc. in March 2026 to support its upcoming commercial launch activities and continued development of its embolic protection technology platform. This funding positions Emboline for commercial introduction in the United States and Europe.

The leadership team at Emboline brings substantial expertise to the medical device sector. Scott Russell serves as President and CEO, leveraging over 30 years of experience in medical device innovation, engineering, intellectual property development, marketing, and executive management. Dr. Amir Belson, as Founder and Chief Technology Officer, holds over 750 issued and pending patents and has founded several successful medical device ventures. Mark Caires, Chief Financial Officer, contributes over 30 years of strategic financial leadership in scaling venture-backed medical device companies. Laura Brenton, Senior Vice President of Clinical and Medical Affairs, has over 25 years of leadership experience in clinical development, regulatory strategy, and global commercialization within the medical device industry.